



JOINT WORKING EXECUTIVE SUMMARY

Project Title: Sub-Regional Cancer Services Pharmacist to support implementation of the Carter Review

Project description:

The Carter Review sets out plans for 80% of pharmacist time to be either clinical or associated with medicines assurance roles and to collaborate or outsource infrastructure services. The County Durham & Darlington NHS Foundation Trust is already achieving in excess of 75% of pharmacist time in these roles. In implementing the Carter recommendations the trust is keen to test new models and concepts beyond the defined infrastructure areas suggested by Lord Carter by combining clinical and infrastructure roles. Roche and the County Durham & Darlington NHS Foundation Trust are keen to work in collaboration to pilot a proof of concept new model of pharmacy service to meet the expectations of the Carter Review.

Joint Working partnership organisation:

County Durham and Darlington NHS Foundation Trust

Other NHS organisations involved:

South Tees Hospitals NHS Foundation Trust

North Tees & Hartlepool NHS Foundation Trust

Project approach:

The project will scope the current service and problems, identify potential solutions and understand the impact of these solutions economically, to service and patients.

This will be resourced within the trust via secondment of an experienced pharmacist to work across the three trusts in the Tees Valley, for a period of 2 years and the creation of a steering committee for the duration of the joint working collaboration.

During the two year project, the post holder, supported by their Chief Pharmacist and joint working steering committee (comprised of members from the trust and Roche Products Ltd), will demonstrate the value of the post in terms of patient benefit and overall service development and will produce a business case for a consultant pharmacist post to continue and expand on the work achieved during the initial two years. After completion of the project it is anticipated that this post will be funded by the NHS.

The joint working project is limited to infrastructure development only and will not measure specific treatment outcomes or safety.

The project is planned to run for approximately 2 years

Expected outcomes:

Benefits to Patients:

The aim of this post is to improve patient care, across Durham, Darlington and the Tees Valley, by helping to facilitate the provision of resilient, robust and consistent pharmacy cancer and aseptic services and through improved early access to cancer medicines.

Benefits to NHS:

Improved cross trust collaboration. Identify areas of duplication in the current pathway; improve the efficiency and therefore the effectiveness and resilience of the pharmacy cancer and aseptic services team in implementing the Carter Review. The project will aim to provide evidence for provision of longer-term pharmacist infrastructure within Durham, Darlington and Tees Valley and provide a model that could be scaled up.

Benefits to Roche:

An improved understanding of the current and future models of pharmacy provision of cancer services within a sub-region of the North of England. Roche Products Ltd manufacture cancer medications across several therapy area and want to collaborate with the NHS to find the most efficient and effective model of care for patients. The service redesign model could be replicated as a blueprint in the wider NHS supporting other trusts in England and Scotland as the Carter review is implemented.

Resource Breakdown:

Roche Products contribution to the joint working project is £119,191 which will be used to partially fund (80%) the secondment of an experienced pharmacist to work across the three trusts in the Tees Valley, for a period of 2 years; members of Roche staff will also provide project management support and be members of the project steering committee.

County Durham & Darlington NHS FT will contribute 20% of funds for seconded pharmacist post (£29,798) and £98,100 in estimated prorated NHS Personnel resource equivalent as part of the steering committee and other NHS personnel input into the project.

This document has been produced by Roche Products Ltd.